Monthly Formulary Amendments – September 2023

Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines.  This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.

This edition covers guidance and alerts published in September 2023.

It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

Prescribing Update Newsletter – September 2023

Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.

If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net

This month’s edition focuses on our Medicine Value bulletins, the environmental impact of inhaler disposal, and the recent National Patient Safety Alert on the shortage of ADHD medications. It also includes another in the series of “Meet the Team” where you can get to know the people behind the work we do. There is also information on serious shortage protocols, some key medicines availability issues, UK product launches, and the RDTC attendance at the forthcoming Clinical Pharmacy Congress (CPC) in November.

View the preview below on desktop, or click here to download a copy.

Defining the type-2 diabetic population: a first step to understanding the impact of pathway choices

Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System leaders. The aim of this report is to determine current prescribing patterns and prescribing costs of antidiabetic treatments across the ICBs in the North of England with a particular emphasis on SGLT-2 inhibitors and GLP-1 mimetics. This will enable organisations to audit current practices against updated NICE guideline recommendations, and to estimate the financial and resource implications of prescribing SGLT-2s to a wider population.

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Budget impact of paracetamol 250mg/5ml oral suspension

The purpose of this bulletin is to highlight the increase in cost of paracetamol 250mg/5ml oral suspensions since May 2022. It considers the potential savings that could be achieved through cost-effective paracetamol suspension prescribing across the ICSs in the North East & Yorkshire region and Greater Manchester.

Budget impact of emollient bath and shower preparations

The purpose of this bulletin is to promote cost effective prescribing by highlighting the lack of evidence on the efficacy of emollient bath and shower preparations for the management of atopic eczema, in line with updated NICE guidance. It considers the potential savings that could be achieved with reduced prescribing of these products across the ICSs in the North East & Yorkshire region and Greater Manchester.

Monthly Horizon Scanning Report – September 2023

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Pain Management

Overview

This report looks at prescribing trends in primary care in relation to Pain Management at ICB and Sub Integrated Board location (SICBl) with particular focus on Opioid and Non-opioid analgesics, Neuropathic pain, Antimigraine drugs and Osteoarthritis.

If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net

Frequency

Bi-annually

Data Period

October 2020 to September 2023

Population demographics of patients prescribed opiates – Feeling the Pain 2022

This poster was first presented at Feeling the Pain: Reducing Harm Caused by Opioids for Non-Cancer Pain, in November 2022. It aims to support greater understanding of the patient populations prescribed opioids, the demographics and the inter-relationships and dependencies between prescribing; find the poster and abstract below.

Download the poster here.

An abstract is also available.

Formulary assessment – Glucagon (Ogluo)

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

Comparison of DPP-4 inhibitors (Gliptins)

Comparison documents are designed to support prescribers and medicines management teams to maximise health gains through the optimum use of medicines within a specific therapeutic area.

There are currently five dipeptidyl peptidase-4 (DPP-4) inhibitors (or gliptins) available in the UK for the management of type 2 diabetes mellitus. There are a number of differences between the DPP-4 inhibitors in terms of licensing, interactions, renal impairment dose adjustment, hepatic impairment dose adjustment, and cost. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these medicines.